2nd Annual Best Practice in Clinical Site Selection & Management

2-4 March, 2009, Cascais (Lisbon), Portugal.
This event will present a fresh and original perspective on improving the performance of clinical trials. It will be looking at improving efficiency when selecting clinical sites and managing an individual site's performance.

This event will be unique because other events are all looking at the same broad, big picture, overall, general, top-down, approach to improving clinical performance. The difference with this event is that the conference will be looking specifically at best practice at the individual site level and what can be done to maximize quality, increase patient recruitment and retention and save time at each single site. Assuming performance can be maximised at each individual site, then the overall global clinical trial will be naturally faster and more productive across all sites.

Find your reasons to attend

  • Meet experts dealing with challenges faced directly at the site on a daily basis.
  • Understand the perspectives of all stakeholders involved, i.e. sponsors, CROs, SMOs and the actual clinical sites.
  • Come to benchmark, share experience and help to develop a best-practice approach to site selection and patient recruitment performance.
  • Build stronger relationships upon a better understanding of the challenges faced by each group, who are all vital to the success of a study.
  • Participate in post-conference interactive workshop focused on maximising site performance by improving relationships between sponsor/CRO and site clinical teams.

Who will benefit:

  • PHARMA:
    VPs, directors, and managers of:
    Clinical Research, Clinical Operations, Patient Recruitment, Clinical Quality Assurance, Medical Affairs, Regulatory Affairs, Medical Directors Clinical Project Managers, Clinical Study Managers, CRAs
  • CROs and SMOs:
    Business Development, Clinical Operations
  • CLINICAL SITE:
    Professors, Investigators, Study nurses

For further information and registration, please visit:
http://www.nextlevelpharma.com/events/view/20

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...